​Dr. Obeidat compared and contrasted the sensitivity of both EBV+ve and -ve cell lines to venetoclax/ABT199, A1331853, and S63845, which target BCL-2, BCL-XL, and MCL-1, respectively. His results clearly demonstrate that EBV+ve cell lines have higher IC50s and tolerance to venetoclax. Interestingly, the cell lines show greater sensitivity to approaches that combine the inhibitors, which may have clinical relevance. Some of these combinations were found to be synergistic and may overcome the protective effect of BHRF1.​​